Myeloproliferative Neoplasms MPN

Year in Review: Myeloproliferative Neoplasms (02-10-2016)

Individuals dealing with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis, typically experience difficult symptoms, life-threatening complications, and are at risk of progression to... Continue Reading

All Symptomatic Polycythemia Vera Patients May Benefit From Treatment with a JAK2 Inhibitor (12-29-2015)

Patients with polycythemia vera (PV) experience significant symptoms characterized by fatigue, itching, night sweats, bone pain, fever, and undesired weight loss that contribute to a poor quality of life which is often under appreciated by family and... Continue Reading

Jakafi® Appears Safe and Effective in Long-Term Disease Control in Polycythemia Vera (07-7-2015)

In patients with polycythemia vera (PV), the drug Jakafi® (ruxolitinib) can help control disease at least one year. These findings were presented at the 20th Congress of the European Hematology Association in Vienna, Austria, June 11–14, 2015.[1] Polycythemia... Continue Reading

What you Need to Know about Itching and Myeloproliferative Neoplasms (04-21-2015)

What you Need to Know about Itching and Myeloproliferative Neoplasms If you have been diagnosed with myelofibrosis or polycythemia vera, you may have experienced itching as a side effect. Itching occurs as a result of the activity of cytokines (small... Continue Reading

Jakafi® Provides Important Symptom Relief in Patients with Polycythemia Vera (04-14-2015)

A Phase III trial finds that Jakafi® (ruxolitinib) more effectively controls symptoms than standard therapy for patients with polycythemia vera (PV). These findings were published in the New England Journal of Medicine. Polycythemia vera is a slow-growing... Continue Reading

Pacritinib May Be Effective against Myelofibrosis without Risk of Myelosuppression (03-25-2015)

The investigational agent pacritinib appears active against myelofibrosis without the risk of myelosuppression, a common side effect of many drugs used to treat myelofibrosis and other myeloproliferative neoplasms (MPN). The developers of pacritinib,... Continue Reading

Phase III Trial Finds Jakafi Superior to Standard Therapy for Polycythemia Vera (02-17-2015)

A Phase III trial finds that Jakafi® (ruxolitinib) is more effective than standard therapy for patients with polycythemia vera (PV). These findings were published in the New England Journal of Medicine. Polycythemia vera is a slow-growing type of blood... Continue Reading

Myeloproliferative Neoplasms: Making Progress in Polycythemia Vera and Myelofibrosis (01-22-2015)

Myeloproliferative neoplasms (MPN) are a related group of blood cancers. In these disorders, the bone marrow cells that produce blood cells develop and function abnormally. The three main types of MPN are polycythemia vera (PV), essential thrombocythemia... Continue Reading

Protein Inhibitor INCB039110 Appears Active in Myelofibrosis (01-6-2015)

In early analysis from a Phase II clinical trial, the JAK1 inhibitor INCB039110 appears to improve symptoms in patients with myelofibrosis. These findings were presented at the 56th American Hematological Society Annual Meeting and Exposition, December... Continue Reading

Jakafi® Helps Maintain Blood Cells Levels in Polycythemia Vera (12-16-2014)

CancerConnect News: A new drug called Jakafi® (ruxolitinib) appears to help patients with polycythemia vera (PV) maintain hematocrit control more effectively than best available therapy. These findings were presented at the 56th American Hematology Society... Continue Reading

« Previous PageNext Page »